The global GLP-1 analogues market size was assessed at USD 46.70 billion in 2024. The market is expected to flourish and grow from USD 56.62 billion in 2025 to USD 322.85 billion by 2034, denoting a ...
1h
Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...
Rafael Nadal said he has left both a sporting and personal legacy after retiring from professional tennis on Tuesday at the ...
Novo Nordisk rose after the Danish giant launched its Wegovy weight-loss product in China. Merck reported promising trial results for a new, easier-to-administer formulation of its blockbuster cancer ...
Novo Nordisk’s blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles ...
With Wegovy gaining acceptance for China in Q2 2024, this opens the door for Novo Nordisk to gain a foothold in a potentially ...
Novo Nordisk has launched Wegovy – its popular weight loss treatment – in China. China, with a population of 1.4 billion, has ...
Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...
FRANKFURT (Reuters) - Healthcare executives and investors expect an uptick in initial public offerings and corporate ...
A Swedish official said Tuesday that the country was investigating a damaged telecommunications undersea cable linking ...
In a study by the Northwestern Medicine Canning Thoracic Institute in Chicago, the RNA in the SARS-CoV-2 virus was found to "trigger the development of a unique type of immune cell with anti-cancer ...
The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback